| Accession |
PRJCA015650 |
| Title |
HLX10 monotherapy has undergone a phase II clinical study of unresectable or metastatic highly microsatellite unstable or mismatched repair defective solid tumors that have failed standard therapy |
| Relevance |
Medical |
| Data types |
PK and ADA
|
| Organisms |
Homo sapiens
|
| Description |
Standard therapy-failed, unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficiency (dMMR) solid tumors Primary Research Objective: To evaluate the clinical efficacy of HLX10 in patients with unresectable or metastatic MSI-H or dMMR solid tumors who develop disease progression or intolerable toxicity after standard therapy. |
| Sample scope |
Monoisolate |
| Release date |
2023-03-20 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| No funding support
|
|
|
|
|
|
| Submitter |
Li
Jin (lijin@csco.org.cn)
|
| Organization |
Shanghai East Hospital |
| Submission date |
2023-03-20 |
